NK1 receptor antagonists: all 244 studies that test it
Page 2 of 3. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.
- A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy WomenCompletedNCT06219902Phase 1
- Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor PatientsCompletedNCT06007586Phase 3
- Antiemetic Prophylaxis With Fosaprepitant and Ondansetron in Patients Undergoing Thoracic SurgeryStatus unknownNCT05881486Not applicable
- The Effect of Aprepitant Reducing Postoperative Nausea and VomitingStatus unknownNCT05772676Phase 4
- Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV.Status unknownNCT05755659Not applicable
- Postoperative Nausea and Vomiting in Laparoscopic Abdominal SurgeryStatus unknownNCT05632224Phase 4
- Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal CancerCompletedNCT05564286Phase 3
- A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy ParticipantsCompletedNCT05481528Phase 1
- A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female ParticipantsCompletedNCT05471817Phase 1
- A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 YearsCompletedNCT05381142Phase 1
- A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male ParticipantsCompletedNCT05351892Phase 1
- Efficacy and Safety of Fosaprepitant in Preventing Chemotherapy-induced Vomiting in Children Treated With Medium and High Emetic Chemotherapeutic DrugsStatus unknownNCT05230654Not applicable
- Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery.TerminatedNCT05189756Phase 4
- A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work NormallyCompletedNCT05071729Phase 1
- A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy AdultsCompletedNCT05061563Phase 1
- A Study to Learn What Happens to Elinzanetant in the Body When Taken With or Without Carbamazepine, and How Safe it is in Healthy Men and Women Aged 18 to 60 Years.CompletedNCT05028608Phase 1
- A Study to Learn How Safe Elinzanetant is, How it Affects the Body, and How it Moves Into, Through and Out of the Body After Single and Multiple Doses in Japanese Healthy Female AdultsCompletedNCT04981431Phase 1
- A Study to Learn How Different Levels of Decreased Liver Function Influence Blood Levels of Elinzanetant Compared to Normal Liver Function in Male and Female ParticipantsCompletedNCT04903821Phase 1
- A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy ParticipantsCompletedNCT04889287Phase 1
- Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner PatientsStatus unknownNCT04873284Not applicable
- Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the BodyCompletedNCT04845841Phase 1
- Mass Balance Study of [14C]-NT-814 Oral Suspension in Healthy Male SubjectsCompletedNCT04654897Phase 1
- Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal CarcinomaCompletedNCT04636632Phase 1
- Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric PatientsCompletedNCT04508400Phase 2
- Influence of Antipruritics on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.CompletedNCT04399148Not applicable
- Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and VomitingCompletedNCT04013386Phase 4
- Rolapitant Plus Olanzapine in Multiday Cisplatin ChemotherapyWithdrawnNCT03960151Phase 2
- Relative Bioavailability of NXP001 Compared to Emend® in Healthy VolunteersCompletedNCT03889366Phase 1
- Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative NeoplasmsCompletedNCT03808805Phase 3
- Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic ChemotherapyCompletedNCT03674294Phase 3
- PALONOSETRON X FOSAPREPITANT IN PONVStatus unknownNCT03586817Phase 4
- Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCCCompletedNCT03572829Phase 2
- Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult VolunteersCompletedNCT03245918Phase 1
- Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer PatientsCompletedNCT03079219Phase 3
- Importance of Substance P in Intracranial Pressure Elevation Following Traumatic Brain InjuryWithdrawnNCT03035838Early Phase 1
- Effects of Aprepitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric EmptyingCompletedNCT02989467Phase 1
- Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction ChemotherapyStatus unknownNCT02979548Phase 3
- Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn InjuryTerminatedNCT02975271Phase 2
- Aprepitant for the Prevention of Chemotherapy-induced Nausea and VomitingStatus unknownNCT02933099Phase 3
- Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal CancerCompletedNCT02909478Phase 3
- NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical StudyWithdrawnNCT02692157Phase 1/2
- Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus TreatmentCompletedNCT02646020Phase 2
- A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell TransplantationStatus unknownNCT02576327Phase 4
- Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal MalignancyTerminatedNCT02550119Not applicable
- Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and DexamethasoneCompletedNCT02532634Phase 4
- Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological SurgeriesCompletedNCT02525848Phase 2/3
- Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin ChemotherapyStatus unknownNCT02445872Phase 2
- Palonosetron Associated to Aprepitant in Prophylaxis of PONVStatus unknownNCT02431286Phase 4
- Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based ChemotherapyStatus unknownNCT02407600Phase 2
- A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy VolunteersCompletedNCT02382666Phase 1
- Neurokinin Receptor Antagonist Associated to Ondansetron in PONVCompletedNCT02357693Phase 4
- Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH)Status unknownNCT02347878Phase 4
- Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed EmesisCompletedNCT02336750Phase 3
- An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous RolapitantCompletedNCT02285647Phase 1
- Aprepitant to Mitigate Opioids' Cognitive Side EffectsStatus unknownNCT02226601Not applicable
- Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic PatientsStatus unknownNCT02205164Phase 2
- Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung CancersCompletedNCT02161991Phase 3
- Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected SubjectsCompletedNCT02154360Phase 1
- Prevention of Nausea and Vomiting in Patients After SurgeryCompletedNCT02021851Phase 4
- VPD-737 for Treatment of Chronic PruritusCompletedNCT01951274Phase 2
- Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.Status unknownNCT01913990Phase 4
- The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and VomitingCompletedNCT01897337Phase 4
- Efficacy of Aprepitant (Emend®) in ChildrenCompletedNCT01661335Phase 3
- Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing ChemotherapyTerminatedNCT01649258Phase 1
- Aprepitant Effects in Intravenous Heroin DependenceCompletedNCT01527994Phase 1
- A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV)CompletedNCT01507194Phase 2
- Aprepitant for Postoperative Nausea and Vomiting in Laparoscopic HysterectomyCompletedNCT01440673Not applicable
- Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving ChemotherapyCompletedNCT01402024Phase 3
- First Time in Human Study (FTIH) With Positron Emission Tomography (PET)CompletedNCT01381419Phase 1
- Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI TrialCompletedNCT01344304Not applicable
- Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg DoseCompletedNCT01300988Phase 1
- Single Dose Safety Study for Compound to Treat Post-Operative Nausea and Vomiting (PONV)CompletedNCT01290133Phase 1
- Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in AdolescentsTerminatedNCT01249001Phase 2
- A Repeat Dose Positron Emission Tomography Study With GSK1144814CompletedNCT01209039Phase 1
- Comparison of Adding EMEND to PONV/PDNV Treatment RegimenWithdrawnNCT01186029Not applicable
- Treatment of Chemotherapy-induced Nausea and VomitingCompletedNCT01101529Phase 2
- Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy SubjectsCompletedNCT01090440Phase 1
- Aprepitant for Prevention of Acute and Delayed Nausea and Vomiting in Patients Receiving a High-emetogenic Dose of Cyclophosphamide for Peripheral Blood Stem Cells HarvestingStatus unknownNCT01088022Phase 3
- Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly CisplatinCompletedNCT01074697Phase 3
- Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid CancerStatus unknownNCT01046461Phase 2
- Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian CancerWithdrawnNCT01017809Not applicable
- Vestipitant 28-day Tolerance StudyCompletedNCT00992160Phase 2
- Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal RadiotherapyCompletedNCT00970905Phase 2
- Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric PatientsCompletedNCT00956215Not applicable
- A Study to Evaluate the Effect of Single Doses of Drug A (Lamotrigine) and Drug B (Vofopitant) Alone and in Combination on Resting Motor Threshold in Healthy SubjectsTerminatedNCT00907985Phase 1
- Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer PatientsTerminatedNCT00869973Phase 3
- Aprepitant in the Prevention of Cisplatin-induced Delayed EmesisTerminatedNCT00869310Phase 3
- A Study of MK0594 in Patients With Alcohol Dependence (0594-020)TerminatedNCT00835718Phase 2
- Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery PatientsCompletedNCT00738621Phase 4
- Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate AbusersStatus unknownNCT00726960Phase 1
- Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast CancerCompletedNCT00719173Phase 1
- Aprepitant PO vs Ondansetron IV for Prevention of Postoperative Nausea and VomitingWithdrawnNCT00699894Not applicable
- A Study to Evaluate the Effects of GW679769 on Sleep and Cognitive Function in Subjects With Primary InsomniaCompletedNCT00650871Phase 2
- A Study With GW597599 And GR205171: Potential New Drugs For The Treatment Of Primary InsomniaCompletedNCT00606697Phase 2
- Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female PatientsCompletedNCT00600990Phase 2
- Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer PatientsTerminatedNCT00588835Phase 4
- The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in SubjectsCompletedNCT00511823Phase 1
- Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Cough From an Unknown Cause (Study P04888)CompletedNCT00506545Phase 2
- Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With CancerWithdrawnNCT00499668Not applicable
- A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy AdultsCompletedNCT00460707Phase 1